KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Invested Capital (2017 - 2025)

Bionano Genomics' Invested Capital history spans 7 years, with the latest figure at $53.5 million for Q3 2025.

  • For Q3 2025, Invested Capital rose 1.65% year-over-year to $53.5 million; the TTM value through Sep 2025 reached $53.5 million, up 1.65%, while the annual FY2024 figure was $39.2 million, 60.83% down from the prior year.
  • Invested Capital for Q3 2025 was $53.5 million at Bionano Genomics, up from $49.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $377.6 million in Q1 2021 and bottomed at $39.2 million in Q4 2024.
  • The 5-year median for Invested Capital is $218.6 million (2023), against an average of $192.0 million.
  • The largest annual shift saw Invested Capital skyrocketed 2860.05% in 2021 before it plummeted 63.2% in 2024.
  • A 5-year view of Invested Capital shows it stood at $341.1 million in 2021, then fell by 25.73% to $253.3 million in 2022, then tumbled by 60.52% to $100.0 million in 2023, then plummeted by 60.83% to $39.2 million in 2024, then surged by 36.69% to $53.5 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Invested Capital are $53.5 million (Q3 2025), $49.1 million (Q2 2025), and $52.0 million (Q1 2025).